tiprankstipranks
Trending News
More News >

Unicycive Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $9 price target Unicycive is a clinical stage biotechnology company developing novel therapies for treating kidney diseases, the analyst tells investors in a research note. The firm expects a positive decision by the FDA for the company’s leading clinical candidate, oxylanthanum carbonate, for lowering high phosphate levels or hyperphosphatemia in chronic kidney disease patients undergoing dialysis and expects management to launch the drug by the end of 2025.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue